Form 4: HilleVax Director Sepulveda Receives Stock Options

Jaime Sepulveda, a director of HilleVax, Inc., was granted stock options for 22,500 shares on June 6, 2024.

Summary

• Jaime Sepulveda, a director at HilleVax, Inc., received stock options on June 6, 2024.
• The options are for 22,500 shares of HilleVax common stock.
• The exercise price of the options is $13.75 per share.
• The options vest on the earlier of the first anniversary of the grant date (June 6, 2025) or the next annual meeting of stockholders, contingent upon continued service on the board.
• The options expire on June 5, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard corporate action (stock option grant) and is generally neutral to positive, as it incentivizes a director to contribute to the company's success.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service on the board.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

Stock option grants are a common form of compensation for directors of publicly traded companies, aligning their interests with shareholders and incentivizing company performance.

Comparison to Industry Standards

• Director compensation packages, including stock options, vary widely across the biotechnology industry depending on company size, stage of development, and board responsibilities.
• Comparing HilleVax's director compensation to peers like Moderna, BioNTech, or Novavax would provide a better understanding of its relative competitiveness.
• Typical vesting schedules for director stock options range from one to three years, with some companies offering immediate vesting upon grant.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns director interests with company performance.
• The director is incentivized to contribute to the company's success, potentially benefiting all stakeholders.

Key Dates

Keywords

HilleVax, stock options, director compensation, Form 4, Sepulveda, HLVX